^
BIOMARKER:

Chr del(17p)

Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
Chr del(17p)
CLL
venetoclax
Sensitive: A1 - Approval
Chr del(17p)
CLL
ibrutinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
Chr del(17p)
CLL
acalabrutinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
Chr del(17p)
CLL
ofatumumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
venetoclax + rituximab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
zanubrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
ofatumumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
CLL
alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
pembrolizumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
nivolumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
duvelisib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
obinutuzumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
pembrolizumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Multiple Myeloma
bortezomib + selinexor
Sensitive: B - Late Trials
Chr del(17p)
Multiple Myeloma
DVD
Sensitive: B - Late Trials
Chr del(17p)
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: B - Late Trials
Chr del(17p)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
Chr del(17p)
CLL
ibrutinib + ublituximab
Sensitive: B - Late Trials
Chr del(17p)
CLL
obinutuzumab
Resistant: B - Late Trials
Chr del(17p)
Multiple Myeloma
Isa-KRd
Sensitive: C2 – Inclusion Criteria
Chr del(17p)
NHL
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
Chr del(17p)
CLL
lenalidomide + tafasitamab
Sensitive: C3 – Early Trials
Chr del(17p)
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
LOXO-305
Sensitive: C3 – Early Trials
Chr del(17p)
CLL
LOXO-305
Sensitive: C3 – Early Trials
Chr del(17p)
Multiple Myeloma
Proteasome inhibitor + Immunomodulator
Resistant: C3 – Early Trials
Chr del(17p)
CLL
RP6530
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
Chr del(17p)
CLL
ICP-022
Sensitive: C3 – Early Trials
Chr del(17p)
CLL
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
Chr del(17p)
CLL
obinutuzumab + zanubrutinib
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab + zanubrutinib
Sensitive: C3 – Early Trials
Chr del(17p)
AML
MGD006
Sensitive: C3 – Early Trials
Chr del(17p)
Multiple Myeloma
melphalan flufenamide
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
FCR
Sensitive: C3 – Early Trials
Chr del(17p)
CLL
FCR
Sensitive: C3 – Early Trials
Chr del(17p)
MDS
azacitidine
Resistant: C3 – Early Trials
Chr del(17p)
Multiple Myeloma
thalidomide
Resistant: C3 – Early Trials
Chr del(17p)
CLL
ibrutinib + UC-961
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
Chr del(17p)
CLL
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
Chr del(17p)
Multiple Myeloma
bortezomib
Sensitive: D – Preclinical
Chr del(17p)
CLL
Compound C
Sensitive: D – Preclinical
Chr del(17p)
CLL
hydroxychloroquine
Sensitive: D – Preclinical
Chr del(17p)
CLL
MRT68921
Sensitive: D – Preclinical